Core Viewpoint - South Korean pharmaceutical company Celltrion plans to invest up to 700 billion Korean won ($478.17 million) to expand capacity at its U.S. factory in response to U.S. tariffs and rising demand [1] Company Summary - Celltrion is responding to U.S. tariffs by increasing its manufacturing capacity in the United States [1] - The investment of 700 billion Korean won is aimed at meeting the growing demand for its products [1] Industry Summary - The pharmaceutical industry is experiencing rising demand, prompting companies like Celltrion to expand their production capabilities [1] - U.S. tariffs are influencing foreign pharmaceutical companies to invest in local manufacturing to mitigate costs [1]

Group 1 - Chapman's, a Canadian ice cream manufacturer, will invest over C$200 million (approximately $144.64 million) to expand its operations in Markdale, Ontario, including a new 175,000-square-foot production facility [1][2] - The initial phase of the new plant will feature three production lines, with operations expected to commence in mid-2026, and an additional three lines planned for installation in 2027 [2] - The expansion is projected to create 200 new full-time jobs and is supported by a loan of up to C$27 million from the Invest Ontario Fund [2][3] Group 2 - The expansion is seen as critical for Chapman's to strengthen its competitive position against increasing competition from multinationals [2] - The new facility will introduce products that have "never before sold in Canada," aiming to enhance Chapman's export business to meet growing international demand [4] - Chapman's offers a diverse range of over 200 products, including ice cream, frozen yogurt, sorbet, and various single-serve novelties [3]